News

Ideas That Generate Results

In recent times, it has been observed that generic cancer drugs are facing severe shortage especially in the US. According to our report, “Global Cancer Generics Market Forecast to 2022”, a major reason for the shortage includes lack of incentive to producers for manufacturing low-cost generics, which presently invokes small profit margins.
 
Recently, an India based drug firm Dr Reddy’s Laboratories launched its generic Decitabine injection used in the treatment of cancer in the US market following approval by the USFDA of its Abbreviated New Drug Applications (ANDA). Similarly, in October 2016, Shilpa Medicare Ltd. received an approval from USFDA for generic Azacitidine injection. This generic drug is used for the treatment of myelodysplastic syndrome. Furthermore, in December 2015, Sun Pharmaceuticals received USFDA approval for the generic version of Novartis AG’s blockbuster cancer drug Gleevec for the treatment of chronic myeloid leukaemia. The Sun Pharma, being the first to file an ANDA for generic Gleevec, was eligible for a 180-day marketing exclusivity in the US, giving the company a headstart before other pharmaceutical companies could also start manufacturing the same drug.
 
All these approvals have given a boost to the morale of Indian cancer generic manufacturers. Other pharmaceutical companies have also entered this field looking at its vast scope in the future.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM862.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm